Main > > >RENAL CELL CARCINOMA. *

---

Kidney Cancer>PostSurgery. Recurrence. Prevention: Sunitinib.
USA Approval Date: 2017. 11.16.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 10.05.




Kidney Cancer>Treat.: Axitinib. (META-
STATIC).
USA Approval Date: 2012. 06.27.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 10.05.




Kidney Cancer>Treat.: Cabozantinib Tablets. (METASTATIC).
Mechanism>Tyrosine Kinases Inh.>AXL, MET
VEGFR-1,2 & 3
CA Approval Date: 2018. 09.19.
EU Approval Date: 2016. 09.09.>
>previously received anti-angiogenic
therapy
EU Approval Date: 2018. 05.17.>
>Previously Untreated First Line Treat.
USA Approval Date: 2016. 04.25.>
>previously received anti-angiogenic
therapy
USA Approval Date: 2017. 12.20>
>Previously Untreated First Line Treat.
Renal Cell Carcinoma (RCC). Treat.:
(*) Companies; Patent; TradeMark & Web-
Site Available on Request
UpDate: 2018. 10.04.




Kidney Cancer>Treat.: CryoAblation System.
Being Used at IL Hospital.
Surgery-Free Technology.
(*) Company; Patents; TradeMark & Web-
Sites Available on Request.
UpDate: 2018. 10.04.




Kidney Cancer>Treat.: Sunitinib. (META-
STATIC).
JP Approval Date : 2008. 04.21.
USA Approval Date: 2006. 01.26.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 10.05.




Kidney Cancer>Treat.: TemSirolimus. (METASTATIC).
Mechanism: mTOR KInase Inhibition.
EU Approval Date : 2007. 11.19.
USA Approval Date: 2007. 05.31.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 10.05.




Kidney Cancer>Treat.: Tivozanib. (META-
STATIC).
Companion Diagnostics> ..
Mechanism: VEGF Inhibition
(*) Companies; Patents; TradeMark &
Web-Site Available on Request.
UpDate: 2018. 10.04.




Treat.: Aldesleukin>(Recombinant IL-2) for Inj.
(METASTATIC)
USA Approval Year: 1992.
(*) Company : Novartis.
Patent : Expired
TradeMark: Proleukin
Web-Site : www.proleukin.com
UpDate: 2018. 10.04.




Treat.: BevacizuMAb BioSimilar+Interfe- ron Alfa
(METASTATIC)
USA Approval Date: 2017. 09.14.
(*) Company : Amgen
TradeMark: Mvasi
UpDate: 2018. 10.04.




Treat.: Everolimus. (METASTATIC).
Mechanism: mTOR Kinase Inhibition.
EU Approval Date : ?
USA Approval Date: 2009. 03.30.
(*) Company : Novartis
Patent : Expired.
TradeMark: Afinitor
Web-Site : www.us.afinitor.com
UpDate: 2018. 10.04.




Treat.: NivoluMAb. (METASTATIC).
Mechanism: PD-1 Inhibitor.
USA Approval Date: 2015. 11.23.
(*) Company : Bristol Myers Squibb.
TradeMark: Opdivo
Web-Site : www.opdivo.com
UpDate: 2018. 10.04.




Treat.: Pazopanib Tablets 200 mg. (METASTATIC).
(*) Company : Novartis.
TradeMark: Votrient
UpDate: 2018. 10.04.




Treat.: Sorafenib. (METASTATIC)
(*) Company : Bayer.
Patent : Expired.
TradeMark: Nexavar.
Web-Site : www.nexavar.com/home/
UpDate: 2018. 10.04.


>RENAL CELL CARCINOMA. *'s products
This section has no products